Gender differences in stage at diagnosis and preoperative radiotherapy in patients with rectal cancer

Cristina Sarasqueta1,2*, Mª Victoria Zunzunegui3, José María Enríquez Navascues4, Arrate Querejeta5, Carlos Placer4, Amaia Perales6, Nerea Gonzalez2,9, Urko Aguirre2,9, Marisa Baré2,7, Antonio Escobar2,8, José María Quintana2,9 and on behalf of the REDISSEC-CARESS/CCR Group

Abstract

Background: Few studies have examined gender differences in the clinical management of rectal cancer. We examine differences in stage at diagnosis and preoperative radiotherapy in rectal cancer patients.

Methods: A prospective cohort study was conducted in 22 hospitals in Spain including 770 patients undergoing surgery for rectal cancer. Study outcomes were disseminated disease at diagnosis and receiving preoperative radiotherapy. Age, comorbidity, referral from a screening program, diagnostic delay, distance from the anal verge, and tumor depth were considered as factors that might explain gender differences in these outcomes.

Results: Women were more likely to be diagnosed with disseminated disease among those referred from screening (odds ratio, confidence interval 95% (OR, CI = 7.2, 0.9–55.8) and among those with a diagnostic delay greater than 3 months (OR, CI = 5.1, 1.2–21.6). Women were less likely to receive preoperative radiotherapy if they were younger than 65 years of age (OR, CI = 0.6, 0.3–1.0) and if their tumors were cT3 or cT4 (OR, CI = 0.5, 0.4–0.7).

Conclusions: The gender-specific sensitivity of rectal cancer screening tests, gender differences in referrals and clinical reasons for not prescribing preoperative radiotherapy in women should be further examined. If these gender differences are not clinically justifiable, their elimination might enhance survival.

Keywords: Rectal Cancer, Gender, Tumor staging, Adjuvant radiotherapy, Delayed diagnosis

Background

Some studies have reported that women have more advanced stages at diagnosis in colorectal cancer [1–6]. In rectal cancer, the evidence is scarce and inconclusive [7–9].

Gender differences in the percentage of patients who have disseminated disease at diagnosis of rectal cancer could be due to differences in diagnostic delay. In a systematic review of 54 studies on pre-hospital delay in the diagnosis of colorectal cancer [10], 5 studies examined gender differences and no robust conclusions could be drawn concerning gender differences in diagnostic delay [11–15]. More recent studies [7, 16] have reported longer intervals from first clinical symptoms to diagnosis in women than in men. To date, none of the studies comparing diagnostic delay in men and women with rectal cancer have attempted to explain the gender differences observed.

Five studies have reported that women are less likely to receive preoperative radiotherapy [17–21], but how a patient’s gender influences clinical management of rectal cancer requires further investigation.
cancer is seldom examined. The aforementioned findings prompt us to question under which circumstances the clinical management of rectal cancer vary between men and women.

The aim of this study was to investigate potential differences in stage at diagnosis and use of preoperative radiotherapy between men and women with rectal cancer. Specifically, we sought to describe the magnitude of any gender differences, and to examine whether they vary by age, or clinical or tumor characteristics.

**Methods**

**Study design and participants**

The CARESS colorectal cancer health services research study was a prospective cohort study conducted at 22 hospitals in 5 autonomous regions in Spain. Patients were eligible if they had undergone curative or palliative surgery for a first-time diagnosis of colorectal cancer made in one of the participating hospitals between April 2010 and December 2012. All cancers were histologically verified carcinomas of the colon or rectum. In the study period, 2986 eligible patients were recruited and of these 237 declined the invitation to participate (7.9% of the men and 8.1% of the women). The remaining 2749 patients were included, 1979 with colon and 770 with rectal cancer. All hospital Institutional Review Boards approved the study and all participants signed an informed consent form. For this sub-analysis, we have included the 770 patients with rectal cancer, 522 men and 248 women [22, 23].

The STROBE reporting guidelines for cross-sectional studies were followed [24].

**Variables**

Data were obtained from medical records at cohort inception [22].

The outcomes of interest are: 1) disseminated or stage IV disease, assessed according to the Pathologic staging of the 7th Edition of the American Joint Committee on Cancer (AJCC) TNM Cancer Staging Manual, considering data on loco-regional staging obtained from histopathological reports, and the diagnosis of distant metastasis based on chest radiography and liver ultrasonography or tomography; and 2) use of preoperative radiotherapy (yes vs no), reflecting whether or not the patient received radiotherapy before surgery.

We refer to gender as a concept encompassing the entangled social and biological differences between men and women. Gender was the explanatory variable in the statistical analyses, 1 for women and 0 for men.

Additionally, we considered the following factors which, according to the literature, might confound or modify the associations between gender and the outcomes of interest:

Patient characteristics: a) age: categorized into three groups (<65, 65 to 80, >80 years), employing the categorization used in previous articles based on this cohort [23]; b) screening status: patients being categorized as screen detected (if diagnosed after a positive fecal occult blood [FOB] test performed as part of population or opportunistic screening) or symptomatic (if diagnosed after having sought medical attention through primary care or emergency services); c) comorbidities: measured using the Charlson comorbidity index [25], classified into three groups (0, 1, and 2 or more); and d) diagnostic delay: number of days between the first contact with a physician and the first positive histological diagnosis, categorized into ≤ and > than 3 months; in patients referred from screening, the date of signing the FOB test report was considered the first contact.

Tumor characteristics: a) distance from the anal verge (<5, 5–10, >10 cm), based on endoscopic and magnetic resonance imaging (MRI) findings; b) pretreatment tumor depth, cT, coded according to the Clinical staging of the 7th edition of the AJCC TNM Cancer Staging Manual: the “T” indicates how deeply the primary tumor has grown into the bowel lining and was assessed by endorectal ultrasound, pelvic computed tomography and/or MRI; and c) histological type: grouped into adenocarcinoma, mucinous adenocarcinoma and undifferentiated carcinomas for the statistical analysis.

**Statistical analysis**

For all the analysis, missing values were included in a separate category. Distributions of the outcomes and covariates were compared between men and women using Pearson’s chi-square test for nominal variables and chi-square test for trend for age. Gender-stratified analysis was conducted to examine the univariate association of each covariate with stage IV and with the use of preoperative radiotherapy, in men and women. For both outcomes, multiple logistic regression models were constructed using generalized estimating equations (GEEs), to account for clustering by hospitals, and fitted using an exchangeable correlation structure. To test for a modifying effect of gender, multiplicative interactions between gender and each covariate were assessed. Such interactions were considered significant if the p-value obtained in the likelihood ratio (LR) test was ≤0.05.

For each significant interaction, analyses were performed stratifying by the values of the variable interacting with gender. The odds ratios for women versus men were estimated using the 95% confidence intervals of the point estimates in the GEE logistic regression models and adjusting for age, comorbidity and any tumor characteristics.
characteristics associated with each outcome with \( p < 0.20 \) in the previous gender-stratified bivariate analyses.

The statistical software used was IBM SPSS v 23. Power calculations for the logistic regression-based estimation of coefficients for binary variables and multiplicative interactions of binary variables were performed with the software developed by Demidenko [26], https://www.dartmouth.edu/~eugened/power-samplesize.php.

**Results**

Table 1 shows that 10.5% of women and 6.5% of men had disseminated disease, with involvement of other organs, \( p = 0.09 \); while 50% of women received preoperative radiotherapy compared to 55.4% of men, \( p = 0.16 \). Men and women differed in level of comorbidity, men being more likely to have a Charlson index being \( \geq 1 \) (\( p < 0.0005 \)); in tumor histology, women being more likely to have an unknown histological type (\( p = 0.04 \)); and in tumor depth, women being more likely to have cT4 disease (\( p < 0.0005 \)). The interval between the first visit and diagnosis was longer in women, with delays > 3 months in 23.8% of women and just 15.7% of men (\( p = 0.02 \)). No significant differences between men and women were found in age, percentage diagnosed through screening or tumor distance from the anal verge.

**Differences in disseminated disease**

The gender-specific distribution of stage IV disease by categories of relevant clinical and tumor variables and gender interactions are reported in Table 2. Among women, stage IV disease was more common among screen-detected cases and those with an unknown referral route; while among men, a higher percentage of stage IV disease was observed when they had not been diagnosed through screening (\( p \) value for gender interaction = 0.002). Regarding diagnostic delay, among women, stage IV disease was more common in those with delay greater than 3 months, while among men, stage IV disease was more common in those with shorter delays (\( p \) value for gender interaction = 0.004).

Table 3 presents the results of the associations between gender and stage IV in each stratum of these two interacting factors: screening status (screen-detected, symptomatic, or unknown referral route) and diagnostic delay (\( \leq 3 \) months or unknown diagnostic delay) (Table 3). The unadjusted OR for disseminated disease was 6.9-fold higher in women than in men among screen-detected cases and 3-fold higher in women than in men among cases with unknown screening status, while no significant gender differences were observed in the probability of disseminated disease among those that had presented with symptoms. Among patients with a diagnostic delay > 3 months, disseminated disease was more common in women than in men (unadjusted OR = 6.3; 95% CI, 1.6–24.9), while no significant gender difference was found in patients with delays \( \leq 3 \) months.

The women-to-men odds ratios were adjusted for age, comorbidities and preoperative radiotherapy. The historical classification was not included in this analysis as it had very few or no observations in some categories and this lack of information hindered convergence of the estimation algorithm. After adjustment, the associations were maintained but the large confidence intervals indicate a lack of precision in these OR estimates attributable to the small sample size in some strata. Power analyses are reported in supplementary material. (Online Resource, Supplementary Table 1).

**Differences in the use of preoperative radiotherapy**

Table 4 shows a gradient of decreasing use of preoperative radiotherapy with age and this gradient is sharper in men, with a significant interaction between age and gender (\( p \) value of LR test for interaction = 0.015). As expected, we observed a greater likelihood of preoperative radiotherapy with increasing tumor depth, in both men and women, although the gradient appeared somewhat steeper in men. The large proportion of missing values of tumor depth both in men and women attenuated the significance of the gender and tumor depth interaction test (\( p \) value of LR test for interaction = 0.20). Hence, we tested for this interaction in the stratified GEE analyses since the percentage of patients on preoperative radiotherapy among those with large and very large tumors (cT3 and cT4) suggested that it was more commonly used to reduce tumor size in men than in women (77.5 and 85.7% in men vs 67.5 and 67.6% in women).

Table 5 shows the ORs for receiving preoperative radiotherapy, comparing women and men, as a function of these strata. Among patients under 65 years old, women were less likely to receive preoperative radiotherapy. This association was confirmed after adjusting for comorbidity and distance from anal verge (adjusted OR = 0.6; 95% CI, 0.4–1.0), while in individuals over 65 years of age, no significant differences were found between men and women. Among patients with large tumors (cT3-cT4), the women-to-men adjusted OR for receiving preoperative radiotherapy was 0.5 (95% CI, 0.4–0.7), adjusting for comorbidity and distance from anal verge.

For each outcome, we carried out sensitivity analysis using only cases with complete data. Results are presented in supplementary material (Online Resource, Supplementary Tables 2 and 3). Regression coefficients were of similar magnitude but standard errors were larger than in the analysis including the categories for missing information.
Table 1  Study outcomes and selected clinical characteristics by gender

|                                | Men  | Women | p-value\(^1\) |
|--------------------------------|------|-------|---------------|
| **Pathological stage**         |      |       |               |
| 0, I                           | 192  | 100   | 0.09          |
| II                             | 144  | 53    |               |
| III                            | 152  | 69    |               |
| IV                             | 34   | 26    |               |
| **Preoperative radiotherapy**  |      |       |               |
| No                             | 233  | 124   | 0.16          |
| Yes                            | 289  | 124   |               |
| Unknown                        | 25   | 17    |               |
| **Age**                        |      |       |               |
| 65 years                       | 221  | 108   | 0.68\(^2\)    |
| 65–80 years                    | 245  | 105   |               |
| > 80 years                     | 56   | 35    |               |
| **Charlson index**             |      |       |               |
| 0                              | 258  | 165   | < 0.0005      |
| ≥ 1                            | 264  | 83    |               |
| **Screening**                  |      |       |               |
| No                             | 429  | 201   | 0.48          |
| Yes                            | 68   | 30    |               |
| Unknown                        | 25   | 17    |               |
| **Diagnostic delay**           |      |       |               |
| ≤ 3 months                     | 374  | 155   | 0.02          |
| > 3 months                     | 83   | 59    |               |
| Unknown                        | 65   | 34    |               |
| **Distance from anal verge**   |      |       |               |
| < 5 cm                         | 100  | 57    | 0.16          |
| 5–10 cm                        | 218  | 83    |               |
| > 10 cm                        | 167  | 90    |               |
| Unknown                        | 37   | 18    |               |
| **Histological classification**|      |       |               |
| Adenocarcinoma                 | 474  | 208   | 0.04          |
| Mucinous adenocarcinoma        | 18   | 14    |               |
| Undifferentiated carcinomas    | 6    | 4     |               |
| Unknown                        | 24   | 22    |               |
| **Tumor depth (cT)**           |      |       |               |
| cT1 - cT2                      | 91   | 55    | < 0.0005      |
| cT3                            | 273  | 120   |               |
| cT4                            | 28   | 34    |               |
| Unknown                        | 130  | 39    |               |

Numbers in parentheses correspond to percentages
\(^1\) Pearson chi-square test
\(^2\) Chi-square test for trend

**Discussion**
Our results indicate that a) women are more likely to have disseminated disease at diagnosis, among patients with cancer detected in screening programs and among patients with a diagnostic delay longer than 3 months; and b) women are less likely to receive preoperative
radiotherapy, among patients who are younger than 65 and among patients with large tumors.

**Disseminated disease**
Studies on colorectal cancer have described a higher risk of advanced disease in women [1–4, 27], but none have assessed whether these differences are associated with patient or tumor characteristics. In one study, researchers observed a non-significant trend towards diagnosis at a later stage in men [8]. In rectal cancer in particular, three recent studies have contradictory results. Katzenstein et al. [28] and Lydrup et al. [29] reported that tumor stage was similar in men and women while Martling [18] reported slightly earlier stages in women than in men.

In colorectal cancer, the relationship between diagnostic delay and tumor stage is controversial in part due to differences between studies, specifically, differences in definitions of types and length of delays. In the case of rectal cancer, less is known given the lack of studies focused on this site. A recent seven-cohort study on colorectal cancer concluded that longer diagnostic intervals are associated with more advanced stages of the disease [30] and the results of the Spanish cohort indicated, similar to in our cohort, longer diagnostic intervals in women than in men [16].

|                          | Stage IV |       |       | p-value for gender interaction |
|--------------------------|----------|-------|-------|-------------------------------|
|                          | Men      | Women |       |                               |
|                          | N        | n (%) |       |                               |
| Age                      |          |       |       |                               |
| < 65 years               | 221      | 17 (7.7) | 108  | 14 (13.0) | 0.382  | 0.202 | 0.80 |
| 65–80 years              | 245      | 14 (5.7) | 105  | 10 (9.5)  |       |       |     |
| > 80 years               | 56       | 3 (5.4) | 35    | 2 (5.7)   |       |       |     |
| Charlson index           |          |       |       |                               |
| 0                        | 258      | 19 (7.4) | 165  | 21 (12.7) | 0.44   | 0.10  | 0.33 |
| ≥ 1                      | 264      | 15 (5.7) | 83   | 5 (6.0)   |       |       |     |
| Screening                |          |       |       |                               |
| No                       | 429      | 30 (7.0) | 201  | 17 (8.5)  | 0.43   | 0.07  | 0.002 |
| Yes                      | 68       | 2 (2.9)  | 30   | 5 (16.7)  |       |       |     |
| Unknown                  | 25       | 2 (8.0)  | 17   | 4 (23.5)  |       |       |     |
| Diagnostic delay         |          |       |       |                               |
| ≤ 3 months               | 374      | 29 (7.8) | 155  | 13 (8.4)  | 0.16   | 0.37  | 0.004 |
| > 3 months               | 83       | 2 (2.4)  | 59   | 8 (13.6)  |       |       |     |
| Unknown                  | 65       | 3 (4.6)  | 34   | 5 (14.7)  |       |       |     |
| Distance from anal verge |          |       |       |                               |
| < 5 cm                   | 100      | 3 (3.0)  | 57   | 5 (8.8)   | 0.34   | 0.83  | 0.67 |
| 5–10 cm                  | 218      | 15 (6.9) | 83   | 10 (12.0) |       |       |     |
| > 10 cm                  | 167      | 12 (7.2) | 90   | 10 (11.1) |       |       |     |
| Unknown                  | 37       | 4 (10.8) | 18   | 1 (3.8)   |       |       |     |
| Histological classification|         |       |       |                               |
| Adenocarcinoma           | 474      | 31 (6.5) | 208  | 18 (8.7)  | 0.49   | 0.04  | 0.25 |
| Mucinous adenocarcinoma  | 18       | 0 (0)    | 14   | 1 (7.1)   |       |       |     |
| Undifferentiated carcinomas | 6 | 1 (16.7) | 4    | 1 (25.0)  |       |       |     |
| Unknown                  | 24       | 2 (8.3)  | 22   | 6 (27.3)  |       |       |     |
| Preoperative radiotherapy|          |       |       |                               |
| No                       | 233      | 17 (7.3) | 124  | 17 (13.7) | 0.52   | 0.10  | 0.21 |
| Yes                      | 289      | 17 (5.9) | 124  | 9 (7.3)   |       |       |     |

1 Pearson’s chi-square test  
2 Chi-square test for trend  
3 Likelihood ratio test for gender interaction
Table 3 Odds ratios (women vs men) for stage IV disease by screening status and diagnostic delay

| screening status | Unadjusted | Adjusted | p-value | Adjusted |
|------------------|------------|----------|---------|----------|
| Stage IV OR (95% CI) | p-value | OR (95%) | p-value | OR (95%) | p-value |
| No | 1.23 (0.67–2.16) | 0.48 | 1.04 (0.61–1.77) | 0.89 |
| Yes | 6.9 (0.88–53.96) | 0.06 | 7.20 (0.93–55.79) | 0.05 |
| Unknown | 3.05 (2.27–4.11) | < 0.0005 | 4.26 (3.18–5.72) | < 0.0005 |

Diagnostic delay

| Diagnostic delay | Unadjusted | Adjusted | p-value | Adjusted |
|------------------|------------|----------|---------|----------|
| ≤ 3 months | 1.07 (0.56–2.08) | 0.83 | 0.95 (0.49–1.85) | 0.99 |
| > 3 months | 6.25 (1.57–24.89) | 0.009 | 5.05 (1.18–21.58) | 0.03 |
| Unknown | 3.61 (1.19–10.96) | 0.02 | 3.91 (1.13–13.53) | 0.03 |

Notes:

*a* We used generalized estimating equations to estimate the women-to-men odds ratios (ORs) in each stratum of the variables with significant multiplicative interactions

*b* Adjusted for age, comorbidity, and preoperative radiotherapy

Table 4 Association of preoperative radiotherapy with various factors in men and women

| Preoperative radiotherapy | Men | Women | p-value for gender interaction |
|---------------------------|-----|-------|-------------------------------|
| Age | N | n (%) | p-value | N | n (%) | p-value | p-value for gender interaction |
| < 65 years | 221 | 140 (63.3) | < 0.0005 | 108 | 55 (50.9) | 0.32 | 0.015 |
| 65–80 years | 245 | 132 (53.9) | 0.05 | 105 | 56 (53.3) | 0.02 | 0.73 |
| > 80 years | 56 | 17 (30.4) | 0.05 | 35 | 13 (37.1) | 0.02 | 0.73 |
| Charlson index | 0 | 258 | 154 (59.7) | 0.05 | 165 | 91 (55.2) | 0.02 | 0.73 |
| ≥ 1 | 264 | 135 (51.1) | 0.05 | 83 | 33 (39.8) | 0.02 | 0.73 |
| Tumor depth | cT1–cT2 | 91 | 18 (19.8) | < 0.0005 | 55 | 10 (18.2) | < 0.0005 | 0.20 |
| cT3 | 273 | 211 (77.3) | 0.05 | 120 | 81 (67.5) | 0.02 | 0.73 |
| cT4 | 28 | 24 (85.7) | 0.05 | 34 | 23 (67.6) | 0.02 | 0.73 |
| Unknown | 130 | 36 (27.7) | 0.05 | 39 | 10 (25.6) | 0.02 | 0.73 |
| Distance from anal verge | < 5 cm | 100 | 69 (69.0) | < 0.0005 | 57 | 34 (59.6) | 0.01 | 0.95 |
| 5–10 cm | 218 | 141 (64.7) | 0.05 | 83 | 48 (57.8) | 0.02 | 0.73 |
| > 10 cm | 167 | 67 (40.1) | 0.05 | 90 | 37 (41.1) | 0.02 | 0.73 |
| Unknown | 37 | 12 (32.4) | 0.05 | 18 | 5 (27.8) | 0.02 | 0.73 |
| Histological classification | Adenocarcinoma | 474 | 267 (56.3) | 0.20 | 208 | 103 (49.5) | 0.63 | 0.97 |
| Mucinous adenocarcinoma | 18 | 8 (44.4) | 0.20 | 14 | 7 (50.0) | 0.63 | 0.97 |
| Undifferentiated carcinomas | 6 | 1 (16.7) | 0.20 | 4 | 1 (25.0) | 0.63 | 0.97 |
| Unknown | 24 | 13 (54.2) | 0.20 | 22 | 13 (59.1) | 0.63 | 0.97 |

Notes:

1 Pearson chi-square test

2 Chi-square test for trend

3 Likelihood ratio test for gender interaction

Table 5 Odds ratios (women vs men) for preoperative radiotherapy by age and tumor depth

| Preoperative radiotherapy | Unadjusted | Adjusted | p-value | Adjusted |
|---------------------------|------------|----------|---------|----------|
| Age | OR (95% CI) | p-value | OR (95%) | p-value |
| < 65 years | 0.60 (0.37–0.97) | 0.04 | 0.58 (0.34–0.99) | 0.04 |
| ≥ 65 years | 0.96 (0.69–1.31) | 0.78 | 0.90 (0.64–1.25) | 0.52 |
| Tumor depth | OR (95% CI) | p-value | OR (95%) | p-value |
| cT1–cT2 | 1.03 (0.47–2.27) | 0.72 | 1.16 (0.52–2.60) | 0.72 |
| cT3–cT4 | 0.58 (0.41–0.84) | 0.003 | 0.51 (0.36–0.74) | < 0.0005 |
| Unknown | 0.86 (0.51–1.44) | 0.56 | 0.83 (0.50–1.37) | 0.47 |

Notes:

*a* We used generalized estimating equations to estimate the women-to-men odds ratios (ORs)

*b* Adjusted for Charlson index and distance from anal verge

*c* To increase the statistical power, we recoded age into two categories (< 65 and ≥ 65 years) and tumor depth into three categories (cT1–cT2, cT3–cT4 and Unknown)
The gender differences we observed in diagnostic delay are especially striking in patients diagnosed with disseminated disease, suggesting that the disease is suspected and confirmed earlier in men than in women, both in cases referred from screening and those who presented with symptoms. Insufficient physical examination has been cited as a main cause of delay [31], but it is not known whether there are actually differences between men and women in terms of the examinations or tests conducted to reach to a diagnosis.

In our study, among patients with delays of more than 3 months, the rate of disseminated disease was higher in women than in men. Similar results were reported by Korsgaard et al. [32], who suggested that the difference was a reflection of the higher proportion of women among over-70-year-old patients, as in this age group there was a strong association between delay and advanced cancer. In our cohort, however, over-65-year-old patients did not have a higher rate of disseminated disease than younger patients. Our results suggest that this effect may be attributable to men having to wait less time for a diagnosis.

A recent study on trends in rectal cancer 5-year survival rates states that the longer survival of women could be due to genetic, hormonal or environmental factors [33], suggesting that the introduction of screening could explain the decrease in differences in survival rates by gender in recent years if men were more likely to participate in screening programs, but this is the opposite of what has been observed in the current study and studies conducted in similar European populations [34–37]. An alternative explanation is that the performance of screening tests, in particular, the sensitivity of the FOB test [37–40], is poorer in women. We observed that among screen-detected cases, the rate of disseminated disease was higher in women than in men. Such gender differences in the sensitivity of the FOB test seem to be largest in the first rounds of screening [38], which is relevant for our cohort whose recruitment coincided with the start of the screening programs in the catchment populations of the participating hospitals.

Recently, results have been published from a randomized clinical trial demonstrating that, after 15 years of follow-up, screening with sigmoidoscopy reduces mortality among men but not among women [41]. Although in colon cancer there are known tumor anatomical and physiological characteristics that may explain these differences [21], there is no such evidence in the case of rectal cancer. On the other hand, it has recently been suggested that the peak in incidence of rectal cancer is earlier in men than in women, and hence, the age range for screening (50–69 years old) might be too young to identify many of the types of cancer that develop in women [42].

Preoperative radiotherapy
We found that women under 65 years of age are less likely to receive preoperative radiotherapy than men of the same age, regardless of having the same level of comorbidity and tumor depth. Previous studies have reported less use of preoperative radiotherapy in women [17–20, 28, 29, 43]. Unlike our results, Paulson et al. found that the differences in preoperative radiotherapy between men and women occurred in those older than 80 years of age. For this part of our analysis, however, given sample size limitations, we classified patients as < or ≥65 years old and the gender difference was only found in the younger patients.

A second factor related to a lower use of radiotherapy in women was tumor depth: among patients with large tumors at diagnosis, women were less likely to receive preoperative radiotherapy. Among patients with cT4 tumors, women had a higher rate of invasion of neighboring organs [5]. Such invasion complicates the administration of radiotherapy and increases the risk of local complications [44], in particular, rectovaginal fistulas. This might explain a tendency to not use preoperative radiotherapy as an initial treatment in women with stage T4 rectal carcinoma with local and regional invasion of an anterior organ. It is not an absolute contraindication to radiotherapy but it is a controversial issue in clinical practice.

Anatomical differences between the pelvis of men and women and their implications for the difficulty of the surgical technique could be another explanation. In particular, in men, who have a narrower pelvis, it might be more difficult to achieve tumor-free circumferential resection margins, implying a greater need for radiotherapy. The scientific evidence available does not support this thesis, however. According to Jeyarajah et al. [45], a Total Mesorectal Excision score of 3, indicating optimal surgical resection, was significantly more likely in men than in women.

Comorbidity could be a contraindication to adjuvant radiotherapy [46]. We found a higher level of comorbidity to be associated with less use of preoperative radiotherapy, and in line with other authors [17, 47], the levels of comorbidity were higher in men. If an influence of comorbidities were to underlie gender differences, the rate of preoperative radiotherapy would be lower in men, but this is the opposite of what we observed.

Strengths and limitations
The main strength of this research is its hypothesis of gender as an effect modifier and therefore, the use of a) gender-stratified analyses of associations between outcomes and known determinants, and b) tests of multiplicative interactions between gender and those determinants. Although conceptually gender is the factor
that modifies the effects of age and the clinical factors on rates of stage IV at diagnosis and preoperative radiotherapy, we have chosen to present the associations of gender with the two outcomes (ORs for women compared with men) seeking to illustrate that being a woman may result in lower chances of early diagnosis and lower chances of preoperative radiotherapy, all other factors being equal. Furthermore, these analyses have revealed gender differences in rectal cancer diagnosis and treatment that would not have been apparent in a risk factor analysis adjusting for gender as a potential confounder.

Additional strengths of this study are the participation of a large number of public hospitals from different geographical areas in Spain. This implies a great diversity of patients covering a wide spectrum of socioeconomic levels and clinical characteristics. Further, we should note two methodological characteristics that strengthen the internal validity of our findings: a) recruitment and data collection were prospective; and b) data were gathered on numerous clinical characteristics potentially associated with the outcomes, enabling us to address potential confounding factors, as well as investigate in which groups of patients and types of tumors any differences observed occur.

The limitations of this study include:

a) Findings are restricted to patients who underwent surgery
b) We are not able to distinguish between screen-detected cases from population screening and opportunistic screening in primary care. Nonetheless, although the strength of the association between screening and stage IV might be influenced by the type of screening, we have no reason to believe that it would depend on gender.
c) Data were missing on tumor depth for a relatively high percentage of patients (22%). It is likely that these patients with missing data had small tumors, given that their rate of radiotherapy was similar to that in patients with small tumors (and very different from that in patients with large tumors). Further, the use of radiotherapy did not differ significantly between men and women with an unknown tumor size.
d) We have conducted multiple comparisons, which increase the probability of reporting spurious associations but the multiple testing has been done according to a recommended analytical strategy for testing gender-linked and gender interactions with potential risk factors as opposed to routinely adjusting for gender or simply reporting gender differences without examining potential effect modification [48].

e) In the analyses of disseminated disease, the large confidence intervals of the estimated women vs men odds ratios indicate that these results are based on few observations in some cells. Therefore, results should be confirmed in large cohorts.

Conclusions
In conclusion, we reported that among patients undergoing surgery for rectal cancer, the risk of having disseminated disease at diagnosis are higher among women when the disease is detected through screening and when there is a diagnostic delay of more than 3 months. Further, among patients under 65 years old or with large tumors, women are less likely to receive preoperative radiotherapy.

These findings open new lines of research on establishing gender-specific cut-offs for FOB tests and investigating whether there are gender differences in the clinical management during the first visit and referrals to specialists and whether there are clinical reasons for not prescribing preoperative radiotherapy in young women and/or women with large tumors. If these gender differences are not clinically justifiable, their elimination might enhance survival.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s12885-020-07195-4.

Additional file 1 Table S1. Power analysis. Table S2. Sensitivity analysis for Stage IV. Table S3. Sensitivity analysis for Preoperative radiotherapy.

Abbreviations
AJCC: American Joint Committee on Cancer; CI: Confidence Interval; FOB: Fecal occult blood; GEE: Generalized estimating eq.; LR: Likelihood ratio; MRI: Magnetic resonance imaging; OR: Odds Ratio

Acknowledgments
We are grateful to the patients who voluntarily took part in this study. We also thank the doctors and all the interviewers from the participating hospitals (Donostia, Bidasoa, Mendaro, Zumárraga, Galdakao-Usansolo, Araba, Basurto, Cruces, Antequera, Costa del Sol, Valme, Virgen del Rocio, Virgen de las Nieves, Canarias, Parc Taulí, Althaia Foundation, del Mar, Clínico San Carlos, La Paz, Infanta Sofía, Alcorcón Foundation, and Doctor Peset), for their invaluable collaboration in patient recruitment, and the Research Committees of the participating hospitals. The Results and Health Services Research in Colorectal Cancer (REDISSEC-CARESS/CCR) Group:

Jose María Quintana López1, Marisa Baré Mañas2, Maximino Redondo Baustista3, Eduardo Briones Pérez de la Blanca4, Nerea Fernández de Llanez Baz5, Cristina Sarasqueta Eizaguirre6, Antonio Escobar Martínez7, Francisco Rivas Ruiz8, María M. Morales-Suárez-Varela9, Juan Antonio Blasco Amaro10, Isabel del Cura González11, Inmaculada Arostegui Madariaga12, Araima Bilbao González13, Nerea González Hernández14, Susana García-Gutiérrez15, green M. Placer Galán16, José María Enríquez Navascués17, Inmaculada Arostegui Madariaga18, Adriana Aramburu19, Mercè Comas Serrano20, Jose María Enríquez Navascués21, Carlos Placer Galán22, Araima Perales Antón23, Ignacio Zabalza Estévez24, José Errasti Alustiza25, Antonio Z Gimeno García26, Santiago Lázaro Asumendi27, José María Erro Azikraete28, Enrique Cormenzana Lizarrabide29, Adela Lastra Muñoz30, Pep Piera Pibernat31, Elena Campano Cuevas32, Ana Isabel Sotelo Gómez33.
Segundo Gómez-Abrih1, F. Medina-Can2, Julia Alcaide3, Arturo Del Rey-Moreno4, Manuel Jesús Alcántara5, Rafael Campo6, Alex Casalots5, Carles Pericay6, María José Gil2, Miquel Pera2, Pablo Collera2, Josep Alfons Espinás6, Mercedes Martínez9, Mireia Espallargues12, Caridad Almazán13, Paula Dujovne Lindenbaum14, José María Fernández-Cebrián14, Rocío Anula Fernández25, Julio Mayol Martínez26, Ramón Cantero Cid34, Héctor Guadalupe Labrador6, María Alexandra Haras Garceau6, Damián García Olmo6, Mariel Morey Montalvo47.

1Research Unit, Galdakao-Umansolo Hospital, Galdakao-Bizkaia / Health Services Research on Chronic Diseases Network (REDISSEC), Spain.
2Clinical Epidemiology and Cancer Screening, Corporación Sanitaria ParcTaulí, Sabadell / REDISSEC, Spain.
3Laboratory Service, Costa del Sol Hospital, Málaga / REDISSEC, Spain.
4Epidemiology Unit, Seville Health District, Andalusian Health Service, Spain.
5Cancer and Environmental Epidemiology Unit, National Center for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.
6Research Unit, Donostia University Hospital / Biodonostia Health Research Institute, Donostia / REDISSEC, Spain.
7Research Unit, Basurto University Hospital, Bizkaia / Biodonostia Health Research Institute - Donostia University Hospital, Paseo Dr. Beguiristain 109 (Gipuzkoa), 20014 Donostia-San Sebastián, Spain.
8Cancer and Environmental Epidemiology Unit, National Center for Biomedical Research in Epidemiology and Public Health (CIBERESP) - Center for Public Health Research (CISPI) - Foundation for the Promotion of Health and Biomedical Research of Valencia Region (FISABIO), Valencia, Spain.
9Health Technology Assessment Unit, Lain Enralgo Agency, Madrid, Spain.
10Research and Teaching Support Unit, Teaching and Research Office, Planning Division, Primary Care Management, Madrid Regional Department of Health, Spain.
11Department of Applied Mathematics, Statistics and Operations Research, University of the Basque Country / REDISSEC, Spain.
12Epidemiology Service, Costa del Sol Hospital, Málaga / REDISSEC, Spain.
13Department of Preventive Medicine and Public Health, University of Valencia / CIBERESP - Epidemiology and Public Health Networking Biomedical Research Centre (CIBERESP) - Center for Public Health Research (CISPI) - Foundation for the Promotion of Health and Biomedical Research of Valencia Region (FISABIO), Valencia, Spain.
14Department of Epidemiology and Cancer Screening, Corporación Sanitaria ParcTaulí, Sabadell / REDISSEC, Spain.
15Department of Medical Oncology, Basurto University Hospital, Bizkaia, Spain.
16Department of General Surgery, Basurto University Hospital, Bizkaia, Spain.
17Department of Histopathology, Galdakao-Umansolo Hospital, Galdakao, Spain.
18Department of General Surgery, Araba University Hospital, Vitoria-Gasteiz, Spain.
19Department of Gastroenterology, Canarias University Hospital, La Laguna, Spain.
20Department of General Surgery, Galdakao-Umansolo Hospital, Galdakao, Spain.
21Municipal Healthcare Institute (IMAS)-Hospital del Mar, Barcelona, Spain.
22Department of General and Digestive Surgery, Donostia University Hospital, Spain.
23Biodonostia Health Research Institute, Donostia, Spain.
24Department of General and Gastrointestinal Surgery, Mendaro Hospital, Spain.
25Department of General and Gastrointestinal Surgery, Zumárraga Hospital, Spain.
26Department of General and Gastrointestinal Surgery, Bidasoa Hospital, Spain.
27Research Unit, Galdakao-Umansolo Hospital, Galdakao, Spain.
28Institute of Biomedicine of Seville (IBIS), Virgen del Rocio University Hospital, Seville, Spain.
29Department of Surgery, Virgen de Valme University Hospital, Seville, Spain.
30Department of General and Gastrointestinal Surgery, Hospital Dr. Peset, Valencia, Spain.
31Department of General and Gastrointestinal Surgery, Costa del Sol Health Agency, Marbella, Spain.
32Department of Medical Oncology, Costa del Sol Health Agency, Marbella, Spain.
33Coloproctology Unit, General and Digestive Surgery Service, Corporación Sanitaria Parc Taulí, Sabadell, Spain.
34Digestive Diseases Department, Corporación Sanitaria Parc Taulí, Sabadell, Spain.
35Pathology Service, Corporació Sanitaria ParcTaulí, Sabadell, Spain.
36Medical Oncology Department, Corporació Sanitaria Parc Taulí, Sabadell / REDISSEC, Spain.
37General and Digestive Surgery Service, Parc de Salut Mar, Barcelona, Spain.
38General and Digestive Surgery Service, Althaia- Xana Asistencial Universitaria, Manresa, Spain.
39Catalanion Cancer Strategy Unit, Department of Health, Catalan Institute of Oncology (ICO), Barcelona.
40Medical Oncology Department, Catalan Institute of Oncology (ICO), Spain.
41Agency for Health Quality and Assessment of Catalonia (AQuAS) / REDISS EC, Spain.
42Agency for Health Quality and Assessment of Catalonia (AQuAS) / CIBERESP, Spain.
43Department of General and Gastrointestinal Surgery, Alcorcón Foundation University Hospital, Madrid, Spain.
44Department of General and Gastrointestinal Surgery, San Carlos University Hospital, Madrid, Spain.
45Department of General and Gastrointestinal Surgery, Infanta Sofia University Hospital, San Sebastián de los Reyes, Madrid, Spain.
46Department of General and Gastrointestinal Surgery, La Paz University Hospital, Madrid, Spain.
47REDISSEC, Research Support Unit, Primary Care Management for the Madrid Region, Madrid, Spain.

Authors’ contributions
Study concepts and design: SC, ZMV, GN, EA, BM, QJM. Data acquisition: SC, PA, EA, BM, EJM, QA, PC, GN, AU, QJM. Quality control of data and algorithms: SC, PA, AU, QJM. Data analysis and interpretation: SC, ZMV, EJM, QA, PC and QJM. Manuscript preparation: SC and ZMV. All authors reviewed and approved the final version of the manuscript.

Funding
This work was supported in part by grants from the Spanish Health Research Fund (PS09/003314, PS09/00910, PS09/00746, PS09/00805, PI09/09460, PI09/09409, PI09/09337, PI09/09453, PI09/09441); Department of Health of the Basque Country (2010111098); KRONIKGUNE–Research Centre on Chronicity (KRONIK 11/006); and the European Regional Development Fund. These grants have been awarded to finance the recruitment of patients, the collection of data from medical records, the sending and collection of self-completed questionnaires, meetings of researchers from participating centers, attendance at scientific meetings to disseminate the results and editing and publishing articles.

Availability of data and materials
Due to a lack of consensus among researchers at all participating centers, raw data is not provided.

Ethics approval and consent to participate
This project was approved by the following bodies in Spain (with the approval reference number, when available, in parentheses): the Ethics Committees of Txagorritxu (2009–20), Galdakao, Donostia (5/09), Basurto, La Paz, Clínico San Carlos, Fundación Alcorcón and Marbella (10/09) hospitals, and the Ethics Committee of the Basque Country (P20140884). All patients were informed of the objectives of the study and invited to voluntarily participate. Patients who agreed to participate provided written consent.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Biodonostia Health Research Institute - Donostia University Hospital, Paseo Dr. Beguiristain s/n (Gipuzkoa), 20014 Donostia-San Sebastián, Spain.
2Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC), Galdakao, Bizkaia, Spain.
3Department of General and Digestive Surgery, University of the Basque Country / REDISSEC, Spain.
4Pathology Service, Corporació Sanitaria ParcTaulí, Sabadell, Spain.
5Department of General and Digestive Surgery, Parc de Salut Mar, Barcelona, Spain.
6Department of General and Digestive Surgery Service, Althaia- Xana Asistencial Universitaria, Manresa, Spain.
7Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC), Galdakao, Bizkaia, Spain.
8Department of General and Digestive Surgery, La Paz University Hospital, Madrid, Spain.
9Department of Medical Oncology, Donostia University Hospital, San Sebastián de los Reyes, Madrid, Spain.
10Department of General and Gastrointestinal Surgery, La Paz University Hospital, Madrid, Spain.
11Research Unit, Galdakao-Umansolo Hospital, Galdakao-Bizkaia / Health Services Research on Chronic Diseases Network (REDISSEC), Spain.
Donostia-San Sebastián, Spain. 2Radiotherapeutic Oncology, Donostia University Hospital, Paseo Dr. Beguiristain 109 (Gipuzkoa), 20014 Donostia-San Sebastián, Spain. 3Biodonostia Health Research Institute, Paseo Dr. Beguiristain s/n (Gipuzkoa), 20014 Donostia-San Sebastián, Spain. 4Clinical Epidemiology and Cancer Screening, Corporación Sanitaria Parc Taulí, Parc Taulí I, 08208 Sabadell, Barcelona, Spain. 5Research Unit, Hospital Basurto, Avda Montevideo, 18, 48013 Bilbao, Bizkaia, Spain. 6Research Unit, Galdakao-Uansanos Hospital, Labeaga Azuza, 48960 Galdakao, Bizkaia, Spain.

Received: 16 April 2020 Accepted: 19 July 2020
Published online: 14 August 2020

References

1. Halpern MT, Pavluck AL, Ko CY, Ward EM. Factors associated with colon cancer stage at diagnosis. Dig Dis Sci. 2009;54(12):2680–93.
2. Morgan JW, Cho MM, Guenzi CD, Jackson C, Mathur A, Natto Z, et al. Predictors of delayed-stage colorectal cancer: are we neglecting critical demographic information? Ann Epidemiol. 2011;21(12):924–10.
3. Mandelblatt J, Andrews H, Kao R, Wallace R, Kerner J. The late-stage diagnosis of colorectal cancer: demographic and socioeconomic factors. Am J Public Health. 1996;86(12):1794–7.
4. Woods SE, Basso S, Engel A. The influence of gender on colorectal cancer stage: the state of Ohio, 1996-2001. J Women’s Health (Larchmt). 2006;15(7):877–81.
5. Komori K, Kinouchi K, Kinoshita T, Sano T, Ito S, Abe T, et al. Sex differences between cT4b and pT4b rectal cancers. Int Surg. 2013;98(3):200–4.
6. Amri R, Bordeianou LG, Sylta P, Berger DL. Gender and ethnic disparities in colorectal cancer stage at diagnosis. Dis Colon Rectum. 2009;52(12):1982.
7. Pita-Fernández S, González-Luján L, López-Calviño B, Seoane-Pillado T, Larrea N, et al. Impact of age on the use of adjuvant treatments in patients undergoing surgery for colorectal cancer: patients with stage II colon or stage II/III rectal cancer. BMC Cancer. 2016;16:435.
8. Sarasqueta C, Perales A, Escobar A, Baré M, Redondo M, Fernández de la Riva N, et al. Impact of age on the use of adjuvant treatments in patients undergoing surgery for colorectal cancer: patients with stage II colon or stage II/III rectal cancer. BMC Cancer. 2019;19(1):735.
9. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61(4):344–9.
10. Charlson ME, Pompei P, Ales KL, Mackenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.
11. Demidenko E. Sample size and optimal design for logistic regression with binary interaction. Stat Med. 2008;27(1):36–46.
12. Amri R, Stronks K, Bordeianou LG, Sylta P, Berger DL. Gender and ethnic disparities in colorectal cancer presentation and outcomes in a US universal health care setting. J Surg Oncol. 2014;109(7):645–51.
13. Katzenstein J, Steirnt R, Ptok H, Otto R, Gastinger I, Lippert H, et al. Gender-specific differences of the early postoperative and oncological long-term outcome in rectal cancer-data obtained in a prospective multicenter observational study. Chirurg. 2018;89(6):458–65.
14. Lydrup ML, Höglund P. Gender aspects of survival after surgical treatment for rectal cancer. Color Dis. 2015;17(5):390–6.
15. Tørring ML, Murchie P, Hamilton W, Vedsted P, Esteva M, Lautrop M, et al. Evidence of advanced stage colorectal cancer with longer diagnostic intervals: a pooled analysis of seven primary care cohorts comprising 11 720 patients in five countries. Br J Cancer. 2017;117(6):889–97.
16. Langenbach MR, Schmidt J, Neumann J, Zimbild H. Delay in treatment of colorectal cancer: multifactorial problem. World J Surg. 2003;27(3):304–8.
17. Korsgaard M, Pedersen L, Sørensen HT, Laurberg S. Reported symptoms, diagnostic delay and stage of colorectal cancer: a population-based study in Denmark. Color Dis. 2008;10(8):668–73.
18. Mitchell E, Macdonald S, Campbell NC, Weller D, Macleod U. Influences on pre-hospital delay in the diagnosis of colorectal cancer: a systematic review. Br J Cancer. 2008;99(6):715–20.
19. Arzouman G, Nilsson E, Stögren-Fordell V, Sjödahl R. A short diagnostic delay is more relevant for rectal cancer than for colon cancer. Eur J Surg. 1996;162(11):899–904.
20. Porta M, Galen M, Belloc J, Malats N. Predictors of the interval between onset of symptoms and first medical visit in patients with digestive tract cancer. Int J Oncol. 1996;8(5):941–9.
21. Esteva M, Leiva A, Ramos M, Pita-Fernández S, González-Luján L, Casamajana M, et al. Factors related with symptom duration until diagnosis and treatment of symptomatic colorectal cancer. BMC Cancer. 2013;13:887.
22. Paulson EC, Wintalla C, Armstrong K, Mahmood NN. Gender influences treatment and survival in colorectal cancer surgery. Dis Colon Rectum. 2009;52(12):1982–91.
23. Martling A, Granath F, Cedernark B, Johannsson R, Holm T. Gender differences in the treatment of rectal cancer: a population based study. Eur J Surg Oncol. 2009;35(4):427–33.
24. Carsin AE, Sharp L, Cronin-Fenton DP, Céleachair AO, Comber H. Inequity in colorectal cancer treatment and outcomes: a population-based study. Br J Cancer. 2008;99(2):266–74.
25. Mak RH, McCarthy EP, Das P, Hong TS, Mamon HJ, Hoffman KE. Adoption of preoperative radiation therapy for rectal cancer from 2000 to 2006: a surveillance, epidemiology, and end results patterns-of-care study. Int J Radiat Oncol Biol Phys. 2011;80(4):978–84.
26. Kim SE, Paik HY, Yoon H, Lee JE, Kim N, Sung MK. Sex- and gender-specific disparities in colorectal cancer risk. World J Gastroenterol. 2015;21(17):5167–75.
27. Quintana JM, González N, Anton-Ladislo A, Redondo M, Bare M, Fernández de la Riva N, et al. Colorectal cancer health services research study protocol: the COR-CARESS observational prospective cohort project. BMC Cancer. 2016;16:435.
28. Sarasqueta C, Perales A, Escobar A, Baré M, Redondo M, Fernández de la Riva N, et al. Impact of age on the use of adjuvant treatments in patients undergoing surgery for colorectal cancer: patients with stage II colon or stage II/III rectal cancer. BMC Cancer. 2019;19(1):735.
44. Abu Gazala M, Wexner SD. Management of rectovaginal fistulas and patient outcome. Expert Rev Gastroenterol Hepatol. 2017;11(5):461–71.
45. Jeyarajah S, Sutton CD, Miller AS, Hemingway D. Factors that influence the adequacy of total mesorectal excision for rectal cancer. Color Dis. 2007;9(9):808–15.
46. Lemmens VE, Janssen-Heijnen ML, Verheij CD, Houterman S, Repelaer van Driel OJ, Coebergh JW. Co-morbidity leads to altered treatment and worse survival of elderly patients with colorectal cancer. Br J Surg. 2005;92(5):615–23.
47. van Leersum NJ, Janssen-Heijnen ML, Wouters MW, Rutten HJ, Coebergh JW, Tollenaar RA, et al. Increasing prevalence of comorbidity in patients with colorectal cancer in the south of the Netherlands 1995-2010. Int J Cancer. 2013;132(9):2157–63.
48. Krieger N. Genders, sexes, and health: what are the connections—and why does it matter? Int J Epidemiol. 2003;32(4):652–7.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.